The FDA has extended its Prescription Drug User Fee Act date for the biologics license application for NT-501, a treatment for macular telangiectasia type 2, according to a press release from Neurotech Pharmaceuticals.
The new date for NT-501 (revakinagene taroretcel), an encapsulated cell therapy, is March 18, 2025. The FDA requested more time to review additional data provided by Neurotech.
“We are committed to providing the agency any information needed to complete the review of the NT-501 BLA,” Richard Small, CEO of Neurotech, said in the press release. “Neurotech will